Novo Nordisk A/S investors may file class action lawsuit over securities fraud allegations.

Levi & Korsinsky, LLP is investigating a class action securities lawsuit against Novo Nordisk A/S (NVO) on behalf of investors who suffered losses between May 7, 2025 and July 28, 2025. The lawsuit alleges securities fraud and seeks to recover losses. Investors can contact Joseph E. Levi, Esq. at [email protected] or (212) 363-7500 for more information.

NEW YORK, Aug. 25, 2025 — Investors in Novo Nordisk A/S (NVO) who suffered losses between May 7, 2025, and July 28, 2025, are encouraged to join a class action securities lawsuit. The lawsuit alleges that Novo Nordisk made materially false and misleading statements about the company's growth potential, particularly concerning its diabetes/obesity drug, GLP-1 [1].

Lawsuit Details

The lawsuit, filed on behalf of investors who purchased or acquired Novo Nordisk securities during the specified period, alleges that the company overstated its growth potential and misrepresented the likelihood of patients transitioning to Novo Nordisk's branded alternatives. These misrepresentations allegedly led to a significant drop in the company's stock price on July 29, 2025, following the announcement of lower sales and profit outlooks [2].

Lead Plaintiff Deadline

Investors have until September 30, 2025, to request that the court appoint them as lead plaintiffs. The lead plaintiff acts on behalf of the class and directs the litigation. Investors can contact Joseph E. Levi, Esq., at [jlevi@levikorsinsky.com](mailto:jlevi@levikorsinsky.com) or (212) 363-7500 for more information [2].

No Cost to Investors

There is no cost to investors to participate in the class action. The law firms representing the class action, including Levi & Korsinsky, LLP, work on a contingency fee basis, meaning they will only be reimbursed for out-of-pocket expenses and attorneys' fees if the lawsuit is successful [2].

Why Join the Class Action?

Joining the class action allows investors to potentially recover losses incurred due to the alleged securities fraud. By working together, investors can hold the company accountable for the misrepresentations and seek compensation for their losses [2].

References

[1] Bernstein Liebhard LLP. (2025, Aug. 25). Shareholder Alert: Bernstein Liebhard LLP Announces a Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NVO). Retrieved from https://www.globenewswire.com/news-release/2025/08/25/3138484/0/en/SHAREHOLDER-ALERT-Bernstein-Liebhard-LLP-Announces-A-Securities-Fraud-Class-Action-Lawsuit-Has-Been-Filed-Against-Novo-Nordisk-A-S-NYSE-NVO.html

[2] Levi & Korsinsky, LLP. (2025, Aug. 25). Levi & Korsinsky, LLP Notifies Investors in Novo Nordisk A/S (NVO) of a Class Action Securities Lawsuit. Retrieved from https://www.morningstar.com/news/globe-newswire/9517949/levi-korsinsky-reminds-shareholders-of-a-lead-plaintiff-deadline-of-september-30-2025-in-novo-nordisk-as-lawsuit-nvo